AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28893921
Drug: Dietary potassium
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary potassium restriction with oral sodium polystyrene sulfonate if needed
Trial: 25851691
Drug: Selexipag with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag with lopinavir/ritonavir (400/100 mg)
Trial: 23504631
Drug: Anisodamine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anisodamine treatment group
Trial: 21392640
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (aspirin and clopidogrel and placebo)
Trial: 19170145
Drug: Rhodiola rosea
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola rosea (SHR‐5) pills
Trial: 19170145
Drug: ADAPT‐232 supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADAPT‐232 supplements
Trial: 15288704
Drug: Regular daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular daily activities in control participants
Trial: 15288704
Drug: Daily activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily activities in depressed participants
Trial: 11743593
Drug: Acyclovir 200
RxNorm normalized name: acyclovir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 200 mg five times daily (n=20)
Trial: 11743593
Drug: Valacyclovir 1000
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 1000 mg twice daily (equivalent to 694 mg acyclovir twice daily) (n=18)
Trial: 8297222
Drug: Urapidil (30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (30mg twice daily, increased to 60mg three times a day)
Trial: 3619586
Drug: Pizotifen (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifen (1.5 mg/day)
Trial: 31315908
Drug: Levosimendan 1
RxNorm normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 1 mg daily
Trial: 31315908
Drug: Levosimendan 1
RxNorm normalized name: Levosimendán
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 1 mg two times a day
Trial: 27159420
Drug: Step down
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step down dose of PPIs by half for 8 weeks
Trial: 27159420
Drug: Continue with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue with the same dose of PPIs for 8 weeks
Trial: 27159420
Drug: Step down
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step down dose of PPIs by half
Trial: 27159420
Drug: Continue with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue with the same dose of PPIs
Trial: 26026502
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (6 g/day)
Trial: 26026502
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (6 g/day)
Trial: 15249757
Drug: Ibuprofen-lysine
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen-lysine
Trial: 2665062
Drug: N-acetylcysteine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (200 mg X 3)
Trial: 31759295
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy for sexuality (MBCT-S) in PP group
Trial: 31759295
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy for sexuality (MBCT-S) in PPHP group
Trial: 22568247
Drug: Diacerein (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein (50 mg Bid, Po) and Celecoxib (0.2 Qd, Po) (control group)
Trial: 19195842
Drug: Allopurinol 300
RxNorm normalized name: allopurinol 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg bid
Trial: 17469006
Drug: Intravenous hydralazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydralazine (5 mg as a slow bolus dose given intravenously, repeated every 20 minutes to a maximum of five doses)
Trial: 17469006
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (20 mg in an intravenous bolus dose followed by 40 mg if not effective within 20 minutes, followed by 80 mg every 20 minutes to a maximum dose of 300 mg)
Trial: 14751924
Drug: Intensive-timing induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive-timing induction therapy
Trial: 11226111
Drug: Preincisional dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preincisional dextromethorphan (120 mg) IM 30 min before skin incision
Trial: 9763820
Drug: Medication during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication during pregnancy
Trial: 7529535
Drug: CY +
RxNorm normalized name: Cys
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CY + etoposide + G‐CSF
Trial: 2913556
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein capsules
Trial: 2913556
Drug: Placebo (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (human albumin powder) capsules
Trial: 1164007
Drug: Gentamicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin with valley levels over 2 mug/ml
Trial: 1164007
Drug: Gentamicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin with peak levels over 10 mug/ml
Trial: 1164007
Drug: Gentamicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin with peaks over 10 mug/ml
Trial: 1164007
Drug: Gentamicin initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin initial doses of 2.0, 1.5, and 1.3 or less mpk
Trial: 1164007
Drug: Gentamicin loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin loading dose of 2 mpk
Trial: 1164007
Drug: Gentamicin at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin at 4.5 mpk daily
Trial: 1164007
Drug: Gentamicin at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin at 3.0 mpk daily
Trial: 31032356
Drug: Caudal Block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal Block (CB) with a dose of 0.5 ml/kg
Trial: 29257010
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (20 mg/kg before incision, 10 mg/kg at 3, 6, 12, and 24 hours) + Topical TXA (1 g) without tourniquet
Trial: 29257010
Drug: Tourniquet +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tourniquet + Intravenous TXA + Topical TXA
Trial: 22379923
Drug: Omeprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (80 mg/day)
Trial: 22379923
Drug: Pantoprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (80 mg/day)
Trial: 19938143
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (tacrolimus, azathioprine, and steroids)
Trial: 17255126
Drug: ACEI+ARB combination
RxNorm normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI+ARB combination
Trial: 15030341
Drug: 0.03% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus ointment applied once daily
Trial: 15030341
Drug: 0.03% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus ointment applied twice daily
Trial: 15030341
Drug: 1% hydrocortisone
RxNorm normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1% hydrocortisone acetate (HA) ointment applied twice daily
Trial: 15030341
Drug: 0.03% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus ointment (both once and twice daily)
Trial: 11505807
Drug: Loratadine 10
RxNorm normalized name: loratadine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 10 mg daily for one month
Trial: 11505807
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antihistamine)
Trial: 9755264
Drug: DTaP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP vaccine (acellular pertussis component DTP vaccine)
Trial: 9755264
Drug: DTP vaccine
RxNorm normalized name: DTP Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP vaccine (whole cell pertussis component DTP vaccine)
Trial: 9755264
Drug: DT vaccine
RxNorm normalized name: Diphtheria Toxoid, Adsorbed/Tetanus Toxoid Intramuscular Suspension [DT VACCINE ADSORBED PEDIATRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DT vaccine (diphtheria and tetanus toxoids vaccine)
Trial: 30940217
Drug: Plant extract
RxNorm normalized name: Plant extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant extract supplement (Aloe gel, grape juice, Polygonum cuspidatum)
Trial: 30047573
Drug: Hydroxychloroquine (HCQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ 200 mg)
Trial: 30047573
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA 81 mg)
Trial: 17239798
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (target INR range 2.0-3.0)
Trial: 17239798
Drug: Aspirin (30-325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (30-325 mg daily)
Trial: 8305412
Drug: Lovastatin alone
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin alone or in combination with fish oil concentrate
Trial: 31815643
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of antibiotic prophylaxis
Trial: 22006873
Drug: Elective left
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective left colectomy for colon cancer (CC)
Trial: 17680654
Drug: PEG-IFN-alpha-2a and
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN-alpha-2a and ribavirin after 14-day dosing period
Trial: 11510709
Drug: Dalteparin 2,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin 2,500 iu, subcutaneously once daily for four or five days post-operatively
Trial: 11510709
Drug: Saline (placebo),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (placebo), subcutaneously once daily for four or five days post-operatively
Trial: 9300751
Drug: Postoperative low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative low dose radiotherapy (5 x 2 Gy; total: 10 Gy)
Trial: 9300751
Drug: Postoperative medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative medium dose radiotherapy (5 x 3.5 Gy; total: 17.5 Gy)
Trial: 28749095
Drug: Remifentanil concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil concentration 2 ng/mL
Trial: 28749095
Drug: Remifentanil concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil concentration 6 ng/mL
Trial: 24366103
Drug: Inosine (500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine (500-mg capsules taken orally up to 2 capsules 3 times per day)
Trial: 19112800
Drug: Fractional photothermolysis
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional photothermolysis treatment
Trial: 16650421
Drug: Single-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose methotrexate (MTX)
Trial: 16650421
Drug: Multiple-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Multiple-dose methotrexate (MTX)
Trial: 12785439
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no extra treatment)
Trial: 9174562
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg daily) + Pindolol (7.5 mg daily)
Trial: 10967371
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg daily) + Placebo
Trial: 17170650
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium
Trial: 29782196
Drug: Topical fluorometholone
RxNorm normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical fluorometholone
Trial: 21041914
Drug: Ritonavir-boosted atazanavir
RxNorm normalized name: atazanavir and ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted atazanavir (ATV/RTV; 300/100 mg once daily)
Trial: 21041914
Drug: Unboosted atazanavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unboosted atazanavir (ATV; 400 mg once daily)
Trial: 16808310
Drug: rHuEPO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO therapy (5000 IU 2 times per week s.c. for 4 months)
Trial: 16808310
Drug: Clinical observation
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical observation (no rHuEPO therapy)
Trial: 1516500
Drug: Morning NPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning NPH insulin
Trial: 23426412
Drug: Retapamulin 1%
RxNorm normalized name: RETAPAMULIN 1% OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retapamulin 1% applied twice daily for 5 days
Trial: 23426412
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied twice daily for 5 days
Trial: 19393841
Drug: 7-day buprenorphine
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-day buprenorphine patches (5, 10, and 20 microg/h, maximum dosage of 20 microg/h)
Trial: 19393841
Drug: Prolonged-release tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tramadol tablets (75, 100, 150, and 200 mg, maximum dosage of 400 mg/d)
Trial: 19393841
Drug: 7-day buprenorphine
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-day buprenorphine patches
Trial: 19393841
Drug: Prolonged-release tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tramadol tablets
Trial: 11430634
Drug: Budipine 10
RxNorm normalized name: budipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budipine 10 mg single dose
Trial: 11430634
Drug: Budipine 10
RxNorm normalized name: budipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budipine 10 mg t.i.d for 10 days
Trial: 11430634
Drug: Budipine 20
RxNorm normalized name: budipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budipine 20 mg single dose
Trial: 11430634
Drug: Budipine 30
RxNorm normalized name: budipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budipine 30 mg single dose
Trial: 7839462
Drug: Preoperative intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative intra-arterial mitomycin-C (10 mg/m2 in 500 ml normal saline over 6 hours)
Trial: 3284340
Drug: norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfloxacin (400 mg every 12 hours)
Trial: 3284340
Drug: cotrimoxazole (160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cotrimoxazole (160/800 mg every 12 hours)
Trial: 30578013
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous (IV) amoxicillin‐clavulanate TID
Trial: 30578013
Drug: 50 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL of IV 0.9% NaCl TID (placebo)
Trial: 28925502
Drug: No-antibiotic regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-antibiotic regimen with supportive care (intravenous fluids, analgesia, and antipyretics as necessary)
Trial: 28925502
Drug: 4-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day course of antibiotics with supportive care
Trial: 28925502
Drug: No-antibiotic regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-antibiotic regimen with supportive care
Trial: 21701333
Drug: Intradermal avotermin
RxNorm normalized name: avotermin
DrugBank: Avotermin (DB11955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal avotermin (200 ng/100 μl/linear cm wound margin)
Trial: 21701333
Drug: Intradermal avotermin
RxNorm normalized name: avotermin
DrugBank: Avotermin (DB11955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal avotermin
Trial: 19114324
Drug: Somatostatin bolus
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin bolus infusion before ERCP followed by continuous infusion for 12 hours
Trial: 19114324
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no somatostatin treatment)
Trial: 16490019
Drug: Sexual counseling
RxNorm normalized name: Zinc Gluconate 50 mg ORAL CAPSULE [Pegasus Male Sexual Enhancer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual counseling and PGE1-intracavernous injection (ICI) therapy (SC+)
Trial: 16490019
Drug: Only PGE1-intracavernous
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Only PGE1-intracavernous injection (ICI) therapy (SC-)
Trial: 14555866
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with antidepressants (started within the first month after stroke)
Trial: 14555866
Drug: Late treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late treatment with antidepressants (started after 1 month)
Trial: 7868799
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) and Chemotherapy (CT)
Trial: 7868799
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (RT and CT)
Trial: 21296694
Drug: Speeda Vero
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speeda Vero cell rabies vaccine (Group A)
Trial: 21296694
Drug: Verorab Vero
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verorab Vero cell rabies vaccine (Group B)
Trial: 18675569
Drug: Systemic alpha-lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic alpha-lipoic acid (ALA) 400 mg
Trial: 18675569
Drug: ALA (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA (400 mg) plus vitamins
Trial: 16893702
Drug: Implanted cardioverter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implanted cardioverter defibrillator therapy
Trial: 15254792
Drug: alpha-dihydroergocryptine (DEC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-dihydroergocryptine (DEC) 101+/−39 mg
Trial: 15254792
Drug: levodopa 369+/−51
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa 369+/−51 mg
Trial: 11766830
Drug: Subcutaneous GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous GH (2 IU daily) for a minimum of 12 weeks
Trial: 9415571
Drug: 2-hour infusion
RxNorm normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-hour infusion of OKT3
Trial: 9415571
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus infusion of OKT3
Trial: 8257887
Drug: Zidovudine 1500
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 1500 mg/day
Trial: 8257887
Drug: Zidovudine 500
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 500 mg/day
Trial: 8257887
Drug: Zidovudine early
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine early treatment
Trial: 31398997
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of dry extract of ginger (5% active ingredient) three times per day for three months